Balancing Potential and Uncertainty: Hold Rating on Amylyx Pharmaceuticals Post-Avexitide Acquisition
Analyst Ratings For Amylyx Pharma
Analysts' ratings for Amylyx Pharma (NASDAQ:AMLX) over the last quarter vary from bullish to bearish, as provided by 5 analysts.The following table summarizes their recent ratings, shedding light on
Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $4 From $3, Maintains Neutral Rating
Amylyx Pharmaceuticals (AMLX) has an average hold rating and price target range of $3 to $8, according to analysts polled by Capital IQ.Price: 2.34, Change: +0.06, Percent Change: +2.41
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper
Amylyx Pharmaceuticals Is Maintained at Neutral by Goldman Sachs
Amylyx Pharmaceuticals Is Maintained at Neutral by Goldman
Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
Goldman Sachs analyst Chris Shibutani maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and raises the price target from $3 to $4.
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 46.2% and a total average
Amylyx Pharmaceuticals: Holding Steady Amidst Expansion and Market Skepticism
Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $4
Goldman Sachs analyst Corinne Johnson maintains $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating, and sets the target price at $4.According to TipRanks data, the analyst has a success rate of 55.7
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
BofA Securities Initiates Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3.5
BofA Securities analyst Charlie CY Yang initiates coverage on $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating, and sets the target price at $3.5.According to TipRanks data, the analyst has a
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Teladoc (TDOC) and Amylyx Pharmaceuticals Inc (AMLX)
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) acquired avexitide from Eiger BioPharmaceuticals Inc (OTC:EIGRQ) for $35.1 million.Avexitide is an investigational, first-in-class glucagon-like peptide-1 (
Amylyx Jumps on Acquisition of Eiger's GLP-1 Drug
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Amylyx Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Acquired Avexitide From Eiger BioPharmaceuticals.
Amylyx Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Acquired Avexitide From Eiger BioPharmaceuticals.
Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Amylyx Pharmaceuticals Inc: Strong Buy Rating on Avexitide's Potential and Strategic Pipeline Expansion
Express News | Eiger BioPharmaceuticals Inc - Sale of Co's Avexitide Asset Closed on July 9
Express News | Amylyx Pharmaceuticals Shares up 8.5% Premarket After Completing Acquisition of Experimental Low Blood Sugar Drug